<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04350255</url>
  </required_header>
  <id_info>
    <org_study_id>STEISURE - Trident II</org_study_id>
    <nct_id>NCT04350255</nct_id>
  </id_info>
  <brief_title>A Register Based Prospective Study During Implementation of a New Cup</brief_title>
  <official_title>STEISURE - Trident II - A Registerbased Multicentric Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stryker Nordic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a prospective register-based study, we aim to evaluate the implant survival, clinical
      outcomes and X-ray findings by following a cohort of patients operated with the Trident II
      cup.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data will be collected from a cohort consisting of minimum 500 total hip arthroplasties. The
      patients will be recruited from multiple high volume centers in Sweden. To determine if there
      is evidence of inferiority as per benchmarking recommendations by The Orthopaedic Data
      Evaluation Panel the following parameters will be studied: Clinical parameters such as EQ-5D,
      Oxford Hip Score and Forgotten Joint Score, preoperative and after 1, 3, 6 and 10 years.
      Conventional radiography will be done preoperatively, postoperatively, 3, 6 and 10 years
      after total hip replacement. CTMA will be done postoperatively, 3 and 6 month and 2 years
      after total hip replacement.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implant survival at 3 years</measure>
    <time_frame>3 years</time_frame>
    <description>Kaplan Meier survival data, cup revision and risk of revision used as endpoints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implant migration measured with Computer Tomography Microanalysis in a subcohort of patients motion Analysis (CTMA) in a sub-cohort of patients</measure>
    <time_frame>CTMA will be done postoperatively, 3 month and 6 months and 2 years after total hip replacement</time_frame>
    <description>Using Computer Tomography Micro-motion Analysis (CTMA) to measure implant migration in a sub-cohort of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant survival at 10 years</measure>
    <time_frame>10 years</time_frame>
    <description>Kaplan Meier survival data, cup revision and risk of revision used as endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>10 years</time_frame>
    <description>Patient-reported generic health outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plain radiographs in a sub-cohort of patients</measure>
    <time_frame>10 years</time_frame>
    <description>Using plain radiographs to evaluate signs of loosening and implant position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events using the national patient register</measure>
    <time_frame>10 years</time_frame>
    <description>ICD codes för surgical and medical adverse events following primary total hip arthroplasty, as defined by the National Board of Health and Welfare will be merged with data in the SHAR (The Swedish Hip Arthroplasty Register). This database includes mainly secondary care visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events using the regional VEGA database</measure>
    <time_frame>10 years</time_frame>
    <description>ICD (International Classification of Diseases) codes för surgical and medical adverse events following primary total hip arthroplasty, as defined by the National Board of Health and Welfare will be merged with data in the SHAR (The Swedish Hip Arthroplasty Register). This regional database includes all contacts (both within primary and secondary care) for patients living in the region of Western Sweden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxford Hip Score</measure>
    <time_frame>10 years</time_frame>
    <description>Patient-reported hip specific outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forgotten Joint Score</measure>
    <time_frame>10 years</time_frame>
    <description>Patient-reported hip specific outcome measure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Prospective</condition>
  <arm_group>
    <arm_group_label>Trident II Hemispherical cup (Stryker Orthopaedics)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total hip arthroplasty using non cemented Trident II Hemispherical acetabular cup</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trident II Tritanium cup (Stryker Orthopaedics)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total hip arthroplasty using non cemented Trident II Tritanium acetabular cup</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total hip arthroplasty</intervention_name>
    <description>Total hip arthroplasty with a Trident II hemispherical cup</description>
    <arm_group_label>Trident II Hemispherical cup (Stryker Orthopaedics)</arm_group_label>
    <arm_group_label>Trident II Tritanium cup (Stryker Orthopaedics)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total hip arthroplasty</intervention_name>
    <description>Total hip arthroplasty with a Trident II Tritanium cup</description>
    <arm_group_label>Trident II Hemispherical cup (Stryker Orthopaedics)</arm_group_label>
    <arm_group_label>Trident II Tritanium cup (Stryker Orthopaedics)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary hip replacement

          -  Eligible for uncemented fixation of the acetabular component

          -  Suitable for one of the stem designs from Stryker Orthopaedics

          -  Accepts follow-up according to the study protocol

        Exclusion Criteria:

          -  Difficulties to understand written information due to language problems or other
             reasons

          -  Use of augments needed

          -  Acute hip fracture

          -  Tumor in the hip joint
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maziar Mohaddes, MD, PhD</last_name>
    <phone>+46730701147</phone>
    <email>maziar.mohaddes@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam Rosenbaum, MD</last_name>
    <phone>+46705330149</phone>
    <email>adamrosenbaum81@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Orthopaedics</name>
      <address>
        <city>Molndal</city>
        <state>Västra Götaland</state>
        <zip>S-43180</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Maziar Mohaddes Ardebili</investigator_full_name>
    <investigator_title>Sahlgrenska University Hospital, Sweden</investigator_title>
  </responsible_party>
  <keyword>Hip arthroplasty</keyword>
  <keyword>Implant survival</keyword>
  <keyword>Clinical outcome</keyword>
  <keyword>X-ray</keyword>
  <keyword>Implant Migration</keyword>
  <keyword>Patient reported outcomes</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to regulations associated with national registers in Sweden alla data will be presented on an aggregated level, individual patient data will not be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

